Table 3.
Outcome a of patients.
| Total (n = 42) | A (n = 22) | H (n = 20) | Estimate b with 95% CI | p Value c | Not Known d | |
|---|---|---|---|---|---|---|
| Serious adverse events (SAE) | 17/42 (40.5%) | 8/22 (36.4%) | 9/20 (45%) | 0.7 (0.17 to 2.85) | 0.7539 | 0/0 |
| Serious adverse reactions (SAR) | 5/42 (11.9%) | 2/22 (9.1%) | 3/20 (15%) | 0.57 (0.04 to 5.64) | 0.656 | 0/0 |
| Thromboembolic event | 5/42 (11.9%) | 3/22 (13.6%) | 2/20 (10%) | 0.71 (0.05 to 6.97) | 1 | 0/0 |
| Bleeding event | 3/42 (7.1%) | 1/22 (4.6%) | 2/20 (10%) | 0 (0 to 42.9) | 1 | 0/0 |
| Ventilation | 41/42 (97.6%) | 21/22 (95.5%) | 20/20 (100%) | Inf (0.02 to Inf) | 1 | 0/0 |
| Ventilator days | 10 (6–18) | 9 (6–16) | 10.5 (6–18.25) | –1 (–6 to 4) | 0.7241 | 1/0 |
| Extracorporeal membrane oxygenation (ECMO) | 4/42 (9.5%) | 2/22 (9.1%) | 2/20 (10%) | 1.11 (0.07 to 16.77) | 1 | 0/0 |
| Renal replacement therapy (RRT) | 15/41 (36.6%) | 9/21 (42.9%) | 6/20 (30%) | 0.58 (0.13 to 2.47) | 0.5204 | 1/0 |
a Binary data are presented as no./total no. (%), continuous data as medians (25th to 75th percentile), b Odds ratios for binary variables and estimated median difference (A–H) for continuous variables, c Assessed with Fisher’s exact test for categorical variables and the Wilcoxon rank sum test for continuous variables, d Not assessable in the argatroban/heparin group.